At the CphI Ww in Barcellona IBSA presents its innovative solutions for the pharmaceutical market, looking for strategic licensing agreements in countries where it does not operate directly. This year’s focus will be on hyaluronic acid products and infertility treatment.
Following the success of the last editions, IBSA confirms its presence at this year’s CPHI worldwide in Barcelona (24-26 October), where it will bring its innovative solutions for the pharmaceutical market, developed leveraging cutting-edge R&D centers and state-of-the art technology production sites.
In particular, IBSA will present some of its latest hyaluronic acid (HA) solutions, such as the innovative Sinovial® HL pre-filled syringes for intra-articular injection containing hybrid HA: high-molecular-weight HA chains and low-molecular-weight HA chains held together by hydrogen bonds. More recently the Group also launched Sinogel®, prefilled syringe for intra-articular injection containing combined hybrid HA: chains of high-molecular-weight hHA and chondroitin obtained by microbial fermentation, held together by hydrogen. Both these products are manufactured using the innovative patented NAHYCO® technology.
Among its HA-based products IBSA will also present Ialuril® Prefill, prefilled syringe for bladder instillation containing HA and chondroitin. It is indicated to re-establish the glycosaminoglycan layers (GAGs) of the urothelial vesical tissue in cases their loss can cause frequent and recurring problems (such as, for example, cystitis of different etiology).
In addition to HA solutions IBSA is also focusing this year on an innovative solution within its infertility treatment portfolio, which includes gonadotropins of human origin and progesterone. We are talking about Prolutex®, the innovative progesterone in aqueous solution for subcutaneous injections. Prolutex® is indicated for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women.
Finally, Sildenafil Oro-dispersible FILM for ED treatment. The oro-dispersible film is a new drug delivery system consisting in an ultrathin strip (50–150 microns thick) of postage stamp size that could contain one or more active ingredients and suitable excipients. After placing it into the mouth, the film dissolves within seconds, without the need for either water or swallowing.
Established in Lugano in 1945, today IBSA operates in more than 90 countries and 5 continents with 18 subsidiaries in Europe, China and the USA, and employs over 2,200 collaborators distributed among our headquarters, subsidiaries and manufacturing plants.
The Group boasts an extensive finished product portfolio that includes different therapeutic categories, such as prescription drugs, OTC medicines, medical devices and food supplements, and covers 10 therapeutic areas.
IBSA is looking for partners and international distributors for strategic licensing agreements in countries where it does not operate directly with its branches.
Visit us at our stand 3P69
or visit our BD dedicated website for more information: www.businessdevelopment.ibsagroup.com
